BACKGROUND: Complete resection of lung metastases improves survival in patients with osteosarcoma. We evaluated the long-term effect of metastasectomy on pulmonary function of patients treated for osteosarcoma during childhood. STUDY DESIGN: We reviewed the medical records of patients who had pulmonary function tests (PFTs) after metastasectomy for osteosarcoma. Patient, tumor, and treatment variables were abstracted along with PFTs. The PFTs were recorded as a percentage of predicted value and were classified as abnormal for forced vital capacity (FVC) < 80%, forced expiratory volume in 1 second (FEV 1 ) < 80%, total lung capacity (TLC) < 75%, and single breath diffusion capacity for carbon monoxide corrected for hemoglobin (DLCO corr ) < 75%.
Osteosarcoma is the most common primary bone tumor in children and adolescents. 1 The tumor originates in regions of rapid bone growth, most commonly, the distal femur, proximal tibia, and proximal humerus. Approximately 15% to 20% of patients will have metastases at diagnosis 2, 3 ; 75% of these are in the lung. 4, 5 Additionally, more than 30% of patients will develop metachronous lung metastases. 5, 6 The best predictor of survival in patients with lung metastases from osteosarcoma is a complete metastasectomy. 5, [7] [8] [9] Over the last few decades, with progress in staging, local control, and chemotherapeutic regimens, the prognosis for metastatic osteosarcoma has improved, with 5-year disease-free survival rates now reaching 30% to 50%. 1, 3, 10 So, long-term survival after pulmonary metastasectomy for childhood osteosarcoma is achievable.
A few studies [11] [12] [13] [14] have evaluated long-term pulmonary function after pulmonary resection (predominantly lobectomy) for benign childhood disease processes. These series demonstrated a mild decrement in lung volumes on long-term follow-up.
Multiagent chemotherapy and multiple pulmonary metastasectomies are often required to render children with osteosarcoma disease-free. However, this treatment approach has the potential to impair pulmonary function, which may interfere with the ability of long-term survivors to participate in life activities at an optimal level.
The impact of metastasectomy on pulmonary function in long-term survivors of osteosarcoma has not been previously studied. The aim of this study was to describe pulmonary function after metastasectomy in long-term survivors of childhood osteosarcoma.
METHODS

A cohort of patients (St Jude Lifetime Cohort Study
[SJLIFE]) was identified that fulfilled the following criteria: diagnosis of childhood malignancy treated at St Jude Children's Research Hospital, survival !10 years from diagnosis, and current age !18 years. The detailed methods used for ascertainment, recruitment, and evaluation of the members of this cohort have been reported previously. 15 This investigation was approved by the institutional review board at St Jude Children's Research Hospital, and all participants and/or their legal guardians provided informed consent.
The cumulative doses for 32 specific chemotherapeutic agents (5-azacytidine, bleomycin, busulfan, carboplatin, carmustine, cisplatinum, cyclophosphamide [IV or orally], cytarabine [IV, intramuscularly, intrathecally, subcutaneously], dacarbazine, dactinomycin, daunorubicin, dexamethasone, doxorubicin, etoposide [IV, orally], fludarabine, fluorouracil, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, lomustine, melphalan, methotrexate [IV, intramuscularly, intrathecally], nitrogen mustard, prednisone, procarbazine, teniposide, thioguanine, thiotepa, tretinoin, vinblastine, and vincristine), surgical procedures, and radiation treatment fields, dose, and energy source were abstracted from the medical records according to a protocol similar to that used in the Childhood Cancer Survivor Study (CCSS). 16 Participants underwent a risk-based assessment as suggested by the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer (COG Guidelines). 17 The Institutional Review Board (IRB) approved a retrospective review for patients diagnosed with osteosarcoma who were eligible for the SJLIFE study and who had undergone pulmonary metastasectomy for osteosarcoma.
Spirometry measured forced vital capacity (FVC), 18 forced expiratory volume in 1 second (FEV 1 ), 18 and single breath diffusion capacity for carbon monoxide corrected for hemoglobin (DLCO corr ). 19 Total lung capacity (TLC) 20 was determined by body plethysmography. All tests were performed according to the American Thoracic Society standard and expressed as percent of predicted using race, age, and sex appropriate equations. Pulmonary function tests were classified as abnormal for FVC < 80%, FEV 1 < 80%, TLC < 75%, and DLCO corr < 75%. For patients who had more than 1 measurement of PFTs, the most recent values were recorded. Obstructive lung disease (FEV 1 /FVC < 0.70) was evaluated using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. 21 Restrictive lung disease (TLC < 75% predicted) was evaluated using the Guides to the Evaluation of Permanent Impairment. 22 
Statistical methods
Fisher's exact test was used to examine the association between the number of thoracotomies and abnormal values of PFTs, and between the number of lesions resected and abnormal values of PFTs. Data were analyzed with SAS version 9.2 (SAS Institute). Tables 1 and 2, of 26 patients who underwent  pulmonary metastasectomy for osteosarcoma from 1968  to 1998 and who were alive and eligible for SJLIFE, 21 patients had PFTs performed during follow-up, 16 during their SJLIFE on-campus evaluation and 5 at an earlier time but after 1 or more thoracotomies. The mean age at diagnosis was 13.2 AE 4.7 years (SD) and the mean age at PFT evaluation was 34.9 AE 10.9 years (SD). The most recent PFT was performed 20.3 AE 9.0 years (SD) after the final thoracotomy, except in 1 patient whose PFTs were performed after the second and before the third thoracotomy. Most patients were male (n ¼ 14) and Caucasian (n ¼ 16). All primary tumors were located in the extremities (femur, 12, tibia/fibula, 7, humerus, 2). All patients received multiagent chemotherapy. Six patients received bleomycin with a mean dose of 107 mg/m 2 (range 45 to 140 mg/ m 2 ). No patients received carmustine (BCNU) or chest radiation therapy. Four of the 5 who did not return for PFTs were males, all were Caucasian, and all had primary tumors of the lower extremity (femur, 4, tibia, 1). One died due to a widely metastatic second malignant neoplasm (leiomyosarcoma), 1 died from a medication overdose, 2 have participated in SJLIFE as Survey Only, 15 and 1 has not yet been contacted regarding SJLIFE participation.
RESULTS
As shown in
Fifteen patients had a single and 6 patients had !2 thoracotomies (range 2 to 6). Eighty lesions were resected. Lesions were located in the right middle lobe (n ¼ 11), right lower lobe (n ¼ 11), right upper lobe (n ¼ 10), left lower lobe (n ¼ 9), left upper lobe (n ¼ 5), and lingula (n ¼ 2). Nine patients had 2 metastases resected and 12 patients had >2 metastases (range 3 to 12) resected. One patient underwent a middle lobectomy and subsequently a left upper lobectomy (TLC, 71% of predicted at follow-up). One additional patient required a left pneumonectomy (TLC, 66% of predicted at follow-up). All other pulmonary resections consisted of wedge resections. Few patients were smokers; 1 patient had a 17 pack-year history and an additional 3 patients were self-described "social smokers."
Forced vital capacity was abnormal for 40%, FEV 1 Patients with multiple thoracotomies had a higher percentage of abnormal values for TLC, FVC, and FEV 1 , but these differences did not achieve statistical significance except in TLC (Table 3) . Individual PFTs were abnormal in 13.3% (TLC) to 46.7% (DLCO corr ) of patients who had 1 thoracotomy and in 50.0% (DLCO corr ) to 66.7% (FEV 1 , TLC) of patients with !2 thoracotomies. There was a significant association between an increasing number of thoracotomies and abnormal TLC (p ¼ 0.03, Fisher's exact test).
Individual PFTs were abnormal in 11.1% (TLC) to 66.7% (DLCO corr ) of patients who had 2 lesions resected, compared with 30.0% (DLCO corr ) to 50.0% (FEV1) of patients with >2 lesions resected ( Table 4) . There was no statistically significant association between an increasing number of lesions and abnormal values for any of the PFTs.
No patient had evidence of obstructive lung disease (FEV1/FVC < 0.70). Six (28.6%) patients had evidence of restrictive lung disease (TLC < 75% predicted).
Individual PFTs were abnormal in 16.7% (TLC) to 50% (FVC, FEV 1 , DLCO corr ) of patients who had received bleomycin, compared with 33.3% (TLC) to 50% (FEV 1 ) of patients who had not received bleomycin ( Table 5) . None of these differences were statistically significant. One of 6 patients who received bleomycin had evidence of mild interstitial lung disease on chest radiograph, and the other 5 patients had no evidence of interstitial disease.
After excluding the 3 patients with anatomic pulmonary resections (n ¼ 3), 18 patients with PFTs remained. Fourteen had a single thoracotomy and 4 patients had !2 thoracotomies (range 2 to 6). Seven patients had 2 lesions resected and 11 patients had >2 lesions (range 3 to 12) resected. Forced vital capacity was abnormal for 33.3%, FEV 1 for 38.9%, TLC for 22.2%, and DLCO corr for 41.2%. The mean percent of predicted for FVC was 78.7% (SD, 17.8%), FEV 1 was 78.2% (SD, 18.6%), 
DISCUSSION
At least 50% of children with osteosarcoma will develop pulmonary metastases at some point in their disease course. [4] [5] [6] Long-term survival is achievable with multiagent chemotherapy and pulmonary metastasectomy, 10, 23 but its impact on pulmonary function has not been previously studied. Based on data suggesting pulmonary dysfunction after thoracotomy with resection of lung tissue in noncancer populations, we hypothesized that longterm survivors of pulmonary metastasectomy would have a similar risk. In this, the first report of long-term pulmonary function in patients who underwent pulmonary metastasectomy for osteosarcoma in childhood, we demonstrate that a substantial proportion have deficits in pulmonary function.
Several components of treatment regimens for childhood malignancies can produce pulmonary toxicity. Bleomycin therapy has been associated with pulmonary fibrosis, which is dose-related. 24 Kharasch and colleagues 25 performed PFTs at various time points after initiation of therapy in 35 children with osteosarcoma who received multiagent chemotherapy including bleomycin (cumulative dose, 120 to 150 mg/m 2 ). In the first few months, decrements in FEV 1 , TLC, and DLCO corr were seen. Pulmonary function tests performed more than 2 years after therapy did not differ from PFTs done at diagnosis. 25 In our cohort, 6 patients received bleomycin (90 to 140 U/m 2 ), but there was no difference in the prevalence of decreased FVC, FEV 1 , TLC, and DLCO corr between those in this study who had and had not received treatment that included bleomycin. None of the patients in this series received radiation therapy involving the lungs. So the present cohort of patients had few confounding treatment factors, making thoracotomy and metastasectomy the predominant treatment variables.
Previous studies have evaluated pulmonary function in children who underwent pulmonary resection for congenital lobar emphysema and other benign lung diseases. These studies suggested that pulmonary resections during childhood resulted in mild decrements in pulmonary function but were limited by small sample size and evaluations of clinically heterogeneous cohorts. [11] [12] [13] [14] In addition, only the study by McBride and associates 11 evaluated pulmonary function in patients many years (median of 15 years) after undergoing lobectomy during infancy. Even though these patients had, on average, 22% of their total lung tissue by predicted weight removed, vital capacity was normal in 13 of 15 patients and TLC was normal in 14 of 14 patients. The FEV 1 was below normal in 14 of 15 patients, with a mean predicted value of 73%; the mean values for both vital capacity (94%) and TLC (93%) were normal.
In our cohort, the PFTs were performed in adults a mean of 20 years after the last pulmonary metastasectomy. Depending on the specific test considered, 28.6% (TLC) to 47.7% (FEV 1 ) of the results were abnormal. Among the patients who had !2 thoracotomies, abnormal PFT results were identified in 50.0% (DLCO corr ) to 66.7% (FEV 1 , TLC) of patients. Although multiple thoracotomies were associated with more frequent impairment of pulmonary function, reduction in lung volumes was mild and the reduction in lung diffusing capacity was consistent with the reduction in lung volume. This study reports long-term follow-up of pulmonary function of 21 long-term survivors of childhood osteosarcoma. The patients received multiagent chemotherapy, which could complicate interpretation of the results. However, only a few patients received bleomycin and none was administered carmustine or chest irradiation. Some evidence suggests that even adults experience lung growth. 26 Perhaps the multiagent chemotherapy administered to this patient population impairs lung recovery or growth. Additionally, it is possible that other environmental exposures or lifestyle choices over the intervening years affected pulmonary function.
CONCLUSIONS
Children with osteosarcoma who undergo pulmonary metastasectomy can achieve long-term survival. Longterm follow-up reveals that they have mildly impaired pulmonary function when compared with normal subjects. It is imperative that these patients be spared additional pulmonary toxic therapies when possible and be counseled about environmental exposures, such as smoking, which might cause a further decrement in pulmonary function.
